PLUR Stock Forecast: Pluri, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.94
−3.09% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$13.5M
Ticker Nerd rank
17/ 100
Median analyst target
—
Analysts covering
—
Revenue$335K−15.8% y/y
Operating income−$5.5M
Net income−$6.2M
Free cash flow−$4.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.5%
1M
+4.4%
YTD
−68.6%
1Y
−75.9%
From 52W high
−75.9%
From 52W low
+10.6%
$0.85
$3.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pluri, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
17/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Volatility
62
Growth
38
Revisions
20
Issuance
18
Momentum
17
Quality
9
Value
8

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PLUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26PLUR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2025Alliance Global PartnersInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PLUR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PLUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pluri, Inc. returned −75.9% against +6.9% for the S&P 500, dividends included.

PLUR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PLURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
9.3×

Cheaper than 12% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
58.5%

Higher than 72% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pluri, Inc. has a market value of $13.5M and an enterprise value of $46.0M.

  • Revenue in the twelve months to 30 June 2026: $1.0M. The latest quarter shrank 15.8% year on year.

  • Net income over the same four quarters: −$25.4M, a −2496.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.2M.

  • Shares outstanding: 10.8M.

  • Pluri, Inc. employs 92 people — $11K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PLUR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLURPluri, Inc.$13.5M17
ESLAEstrella Immunopharma, Inc.$13.5M26
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
NCELNewCelX Ltd.$13.6M4
ACTUActuate Therapeutics, Inc.$13.6M39
BYSIBeyondSpring, Inc.$13.7M11
TVRDTvardi Therapeutics, Inc.$13.2M30

Take a look at PLUR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pluri, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PLUR

How does Ticker Nerd's model rank PLUR?

As at 21 Nov 2026, Pluri, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

What is the PLUR stock forecast for 2030?

No analyst covering Pluri, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLUR are extrapolating price history, which says nothing about the business.

How has PLUR stock performed over the past year?

Pluri, Inc. returned -75.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pluri, Inc. do?

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies. The company uses its proprietary three-dimensional cell expansion platform to support scalable cell production for applications across regenerative medicine, immunotherapy, food technology, and agricultural technology.

Company

About Pluri, Inc.

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies. The company uses its proprietary three-dimensional cell expansion platform to support scalable cell production for applications across regenerative medicine, immunotherapy, food technology, and agricultural technology. Its current business areas include cell therapeutics, cultivated food solutions, and contract development and manufacturing services, reflecting a diversified platform built around advanced cell engineering. Pluri Inc. serves markets that rely on biological innovation to address medical, industrial, and sustainability challenges, positioning itself as a provider of cell-based solutions for both therapeutic and non-therapeutic uses. Headquartered in Haifa, Israel, Pluri Inc. operates as a clinical-stage biotechnology company with a focus on translating cell technology into practical commercial products and services.

CEO Mr. Yaacov Yanay · 92 employees · Israel · https://www.pluri-biotech.com